

1 **Transplantation and old stem cell age independently increase the risk of clonal hematopoiesis in**
2 **long-term survivors of pediatric HCT.**

3 **Short title:** *Clonal hematopoiesis in survivors of pediatric HCT*

4

5 K.F. Müskens, MD¹, N. Wieringa, MD¹, M. van Bergen, PhD², J.E. Bense, MD PhD³, B.M. te Pas¹, A.P.J.

6 de Pagter, MD PhD³, PhD, A.C. Lankester, MD PhD³, M.B. Bierings, MD PhD¹, D. Neuberg, ScD⁴, S.

7 Haitjema, MD PhD⁵, L.C.M. Kremer, MD PhD¹, G.A. Huls, MD PhD⁶, S. Nierkens, PhD^{1,7}, J.H. Jansen,

8 PhD², C.A. Lindemans, MD PhD¹, A. de Graaf, PhD², M.E. Belderbos, MD PhD¹

9

10 ¹ Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

11 ² Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands

12 ³ Division of Stem cell Transplantation, Department of Pediatrics, Willem-Alexander Children's

13 Hospital, Leiden University Medical Center, Leiden, Netherlands

14 ⁴ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.

15 ⁵ Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands.

16 ⁶ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands

17 ⁷ Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

18

19 **Corresponding author:**

20 M.E. Belderbos

21 Princess Máxima Center for Pediatric Oncology

22 Heidelberglaan 25, 3584 CS Utrecht, The Netherlands

23 Phone: +31 6 26947687

24 m.e.belderbos@prinsesmaximacentrum.nl

25

26 **Data sharing statement:**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Requests about publication-related data can be made via email to the corresponding author.

28

29 **Counts:**

30 Text word count: 2157

31 Abstract word count: 150

32 Number of tables: 1

33 Number of figures: 3

34 Number of references: 25

35

36 Number of supplementary tables: 1

37 Number of supplementary figures: 4

Abstract

38 In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to
39 function far beyond normal human lifespan. Here, we investigated the risk of clonal hematopoiesis
40 (CH) in 144 pediatric long-term HCT survivors, compared to 115 healthy controls. CH was detected in
41 16% of HCT survivors, at variant allele frequencies (VAFs) of 0.01-0.31. Mutations were
42 predominantly in DNMT3A (80%) and TET2 (20%). Older stem cell age and the HCT procedure
43 independently increased the risk of CH (odds ratios 1.07 per year increase ($p < 0.001$) and 2.61 for HCT
44 ($p = 0.02$)), indicating both aging- and transplantation-induced effects. Large clones (VAF > 0.10) were
45 found exclusively in HCT recipients. Notably, CH was also detected within 15 years after cord blood
46 HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies
47 are required to track the evolution of post-transplant CH and its impact on future cardiovascular
48 disease, second malignancies and overall survival.

49

50 Significance statement

51 As the number of long-term HCT survivors continues to increase, so does the population at risk of
52 long-term effects. We demonstrate that pediatric HCT survivors are at increased risk of clonal
53 hematopoiesis compared to the general population. Given the young age of these recipients, our
54 data emphasize the need for prospective studies to assess the potential health consequences of
55 post-transplant CH.

56 **Introduction**

57 Clonal hematopoiesis (CH) refers to the detectable presence of a leukemia-associated mutation
58 without overt hematologic malignancy¹⁻³. In the general population, CH is strongly age-dependent
59 and associated with an increased risk of developing myeloid malignancies, cardiovascular disease and
60 overall mortality^{1,2,4}. Previously, we showed that clonal expansion rates depend on the mutated
61 gene⁵. Still, large variation exists in expansion rates, even in individuals with the same mutation^{5,6}.
62 Which mutation-independent processes drive the expansion of mutant clones remains incompletely
63 understood.

64 Allogeneic hematopoietic cell transplantation (allo-HCT) provides a unique, controlled setting
65 to study the impact of forced proliferation, inflammation and drug therapy on CH. Previous studies
66 have shown that 1) hematopoietic stem cell (HSC) clones with CH driver mutations can be present in
67 HCT donors, even at very young age^{7,8}; 2) donor-derived HSCs with CH mutations can engraft in the
68 recipient⁷⁻¹¹; 3) clone size is generally increased in recipients compared to donors^{9,11}; 4) the extent to
69 which donor-derived mutant clones expand upon transplantation varies largely between
70 individuals^{7,8,10,11}; and 5) forced proliferation of HSCs during hematopoietic regeneration results in
71 DNA damage and telomere shortening¹⁰, which may reduce long-term clonal diversity. While long-
72 term effects are most relevant to HCT recipients transplanted at pediatric age given their long life-
73 expectancy, most studies on post-transplant CH are limited to adults. Moreover, which transplant-
74 related exposures facilitate the preferential outgrowth of CH-mutant over wildtype clones remains
75 unstudied.

76 Here, using a well-annotated cohort of 144 long-term survivors of pediatric HCT, we
77 investigated whether HCT at a young age increases the risk of developing CH and which extrinsic
78 factors may confer a proliferative advantage to CH mutant clones.

79

80 **Methods**

81 A total of 144 long-term survivors of allo-HCT (>5 years post-transplant), who underwent HCT during
82 childhood (≤ 18 years) between 1981 and 2018, were enrolled during post-HCT follow-up at the
83 Princess Máxima Center (PMC) from January 2022 to October 2023 (Supplementary Figure S1).
84 Inclusion criteria were having received an allo-HCT at least five years prior. Exclusion criteria were
85 inability to understand the patient informed consent forms. Patients had been transplanted at the
86 UMC Utrecht/PMC (n=80) or Leiden University Medical Center (n=64). The study was approved by
87 the local ethics committee (NedMec no. NL77721.041.21) in accordance with the declaration of
88 Helsinki. All patients or their caretakers provided written informed consent. Clinical characteristics
89 and demographics were extracted from medical charts. CH was assessed in whole blood collected at
90 study enrolment using a panel targeting 27 myeloid and lymphoid malignancy driver genes, as
91 previously described⁵. Somatic variants were called at variant allele frequency (VAF) ≥ 0.01 and ≥ 10
92 mutant unique reads. To prevent detection of germline variants, variants at VAF > 0.40 were filtered.
93 Post-transplant CH was compared to CH within leftover graft material from healthy donors,
94 unrelated to our survivor cohort¹². Both cohorts were processed and analyzed using the same
95 pipelines. Associations between clinical characteristics and CH were tested using Wilcoxon, Chi-
96 squared or Fisher's exact tests as appropriate. Logistic and linear regression models were used to
97 identify risk factors for the prevalence of CH and VAF, respectively, correcting for potential
98 confounders. Post-transplant viral reactivations were defined as cytomegalovirus, Epstein-Barr-virus
99 and/or adenovirus loads > 1000 copies/mL during pre-emptive screening. For patients transplanted in
100 the UMC Utrecht/PMC, historical laboratory data, including weekly pre-emptive C-reactive protein
101 (CRP) measurements around graft infusion, were available and extracted via the Utrecht Patient
102 Oriented Database¹³.

103

104 **Results**

105 *CH prevalence is higher in long-term survivors of pediatric HCT compared to healthy controls*

106 A total of 144 HCT recipients were enrolled, at a median calendar age of 20.5 years (interquartile
107 range (IQR): 16.2-27.7, Table 1). HSC age (median: 32.1 years, IQR 15.6-43.7) was calculated by
108 summing the donor age at HCT (median: 13.5 years, IQR: 5.1-26.8) and the time between HCT and CH
109 assessment (“follow-up time”, median: 10.4 years, IQR: 8-17.9). In total, we identified 30 CH
110 mutations with VAF ≥ 0.01 in 23 HCT recipients (16%; 95% confidence interval (CI): 10-23%, Figure
111 1B). Mutations were exclusively found in *DNMT3A* (24 mutations, 80%) or *TET2* (6 mutations, 20%).
112 Most were single-base substitutions (23 mutations, 77%), of which 12 were cytosine-to-thymine
113 transitions (Supplementary Figure S2). VAFs ranged from 0.01 to 0.31, with a median of 0.02.
114 Chimerism analysis confirmed that post-transplant CH originated from donor cells in 20 out of 23
115 cases. In the remaining recipients, recipient origin of CH could not be excluded due to residual
116 patient chimerism exceeding the size of the CH clone.

117 To determine whether HCT affects the prevalence and characteristics of CH, we compared
118 our HCT cohort to 115 healthy, untransplanted controls (median age: 48.0 years, IQR: 34.0-56.5,
119 Supplementary Table S1, Supplementary Figure S3). In line with previous studies^{1,2,14,15}, CH was
120 virtually absent in healthy individuals <40 years. In contrast, eight HCT recipients with HSC-ages <40
121 years had detectable CH (Figure 2A). In both cohorts, older HSC age was associated with increased
122 risk of CH (odds ratio 1.07 per year increase, $p < 0.001$, Figure 2A-B and Supplementary Figure S3D).
123 When comparing individuals with similar HSC ages, the age-corrected prevalence of CH was
124 significantly higher in HCT recipients compared to controls (Figure 2A). In the HCT setting, HSC age
125 consists of donor age, reflecting the risk of CH-mutant HSCs being present in the graft, and follow-up,
126 reflecting the time during which mutant HSCs expand or arise in the recipient (Figure 2C-D).
127 Additionally, the calendar age of the recipient at HCT represents the age of the niche receiving the
128 donor HSCs (Figure 2E). In multivariable regression, both donor age and follow-up time were
129 significant predictors of CH (Figure 2F), whilst recipient age at HCT was not ($p = 0.68$).

130 Most CH clones were small, both in HCT recipients and controls (median VAF 0.023 and 0.015
131 respectively, $p = 0.23$, Figure 2G). Notably, very large clones with VAF > 0.10 were exclusively detected

132 in HCT recipients. Although a trend of increased clone size at higher HSC age was observed for both
133 HCT recipients and controls (Figure 2H), this only explained part of the observed variation in clone
134 sizes. In particular, two HCT recipients carried DNMT3A-mutated clones with VAFs of 0.30 and 0.31,
135 at HSC ages of 14.5 and 30.0 years, respectively. Strikingly, the former of these two recipients was
136 transplanted with cord blood, suggesting that even cord blood grafts may contain HSCs with CH
137 driver mutations. Collectively, these data demonstrate that HCT recipients are at increased risk of CH
138 at younger HSC age compared to controls, likely originating from mutant donor HSPCs which
139 preferentially expand in the context of HCT and persist into adulthood.

140

141 *Systemic inflammation is associated with post-transplant CH*

142 To identify HCT-related exposures that may contribute to the development of CH, we compared
143 clinical characteristics between HCT recipients with and without CH. No differences were observed in
144 underlying disease, stem cell source, CD34 dose or donor-recipient relation (Figure 3A). Remarkably,
145 we identified various post-transplant exposures associated with presence of CH. First, CH prevalence
146 was higher in recipients who had received serotherapy as part of their conditioning regimen. After
147 serotherapy administration (usually day -9 to -5 before graft infusion), T-cell lysis can result in an
148 inflammatory response marked by fever and increased C-reactive protein (CRP)¹⁶. To investigate
149 whether HCT recipients with long-term CH had experienced such an inflammatory response, we
150 investigated CRP values around time of graft infusion. Hereto, we extracted CRP values, obtained
151 during pre-emptive monitoring, for all HCT recipients transplanted at the UMC Utrecht/PMC (n=80,
152 Figure 3B-C, Supplementary Figure S4). Within this subset, all HCT recipients that later developed CH
153 had received serotherapy. As expected, serotherapy was associated with a transient CRP rise
154 (Supplementary Figure S4B). Strikingly, CRP levels before and shortly after graft infusion were higher
155 for HCT recipients with subsequent CH compared to those without, both in the overall cohort and
156 within those who had received serotherapy. This difference was not observed at later timepoints. In
157 addition, post-transplant viral reactivations, defined as cytomegalovirus, Epstein-Barr-virus and/or

158 adenovirus loads >1000 copies/mL during pre-emptive screening, were associated with CH in
159 univariable analysis (Figure 3D). Whether this is the consequence of serotherapy or an independent
160 inflammatory event could not be established. We did not observe a significant association between
161 acute graft-versus-host disease (aGvHD) and CH (Figure 3E). None of the HCT recipients in our cohort
162 had developed a secondary hematologic malignancy at time of enrollment.

163

164 **Discussion**

165 Due to the increasing use of HCT as a treatment and improvements in supportive care protocols, the
166 number of long-term HCT survivors continues to increase. While much research has focused on the
167 non-hematopoietic late effects after HCT¹⁷, the long-term effects on the hematopoietic system – the
168 only organ not directly exposed to chemotherapy – remain unclear. Long-term complications are
169 particularly relevant for pediatric recipients, who have a life expectancy of several decades after
170 successful HCT. Here, we demonstrate that long-term survivors of pediatric HCT are at increased risk
171 of CH compared to the general population. Importantly, older HSC age and the HCT procedure itself
172 were independently associated with post-transplant CH, suggesting the involvement of both aging-
173 and transplantation-induced effects. Furthermore, consistent with existing pre-clinical data indicating
174 that inflammation promotes clonal expansion¹⁸, we found an association between post-transplant CH
175 and (serotherapy-induced) inflammation around graft infusion. This supports the hypothesis that
176 systemic inflammation might promote the selection and/or preferential expansion of mutant HSCs,
177 resulting in detectable CH years later.

178

179 Our findings are in line with previous studies in adult HCT cohorts, demonstrating that the prevalence
180 of CH is higher in HCT recipients compared to their donors¹⁹. Using sensitive backtracking studies,
181 most cases of adult post-transplant CH could be traced back to the donor graft, even in very young
182 donors⁷. Furthermore, donor-derived CH clones were more likely to engraft and/or expand after HCT,
183 resulting in an increased clone size in recipients compared to donors^{9,11}. While residual graft material

184 was not available for our study cohort, these transplant donors would be very unlikely to harbor
185 detectable CH clones given their young age. It is important to note that the detection of CH is highly
186 dependent on the sequencing thresholds used, and that CH-negative individuals may still harbor
187 small CH clones below the lower limit of detection. Accordingly, the absence of detectable CH in the
188 HCT donor does not rule out the possibility of mutated HSCs already being present in the graft and
189 becoming detectable in the recipient after HCT. In line with this notion, we found a positive
190 association between donor age and the risk of post-transplant CH. Notably, we also observed CH
191 within 15 years after UCB HCT, which is amongst the youngest cases of CH reported thus far. This is
192 consistent with previous single-cell lineage-tracing²⁰ and twin studies²¹, suggesting that HSCs carrying
193 leukemia-associated mutations might already be present at birth, and only grow out to become
194 detectable clones upon HCT, which creates an environment favoring the selective expansion of
195 mutant HSCs.

196
197 The clinical impact of post-transplant CH remains to a large part unknown. Long-term HCT survivors
198 are confronted with various potential late effects, including second malignancies and cardiovascular
199 disease^{22,23}, which may be affected by or related to the presence of CH^{24,25}. In our cohort, we did not
200 observe any individuals with donor-derived myelodysplasia or secondary hematologic malignancies.
201 Yet, the detection of these complications is better addressed in prospective rather than cross-
202 sectional studies. Notably, we have recently shown that the risk of malignant transformation of CH
203 depends on the mutated gene as well as its growth dynamics⁵. While the observed prevalence of
204 post-transplant CH in young HSCs indicates either a transient or persistent increase in clonal growth,
205 discriminating between these two may identify clones with different risk of malignant progression.
206 Future research should focus on longitudinal monitoring of CH in allo-HCT recipients to investigate
207 growth dynamics and better assess the long-term clinical consequences, including cardiovascular
208 disease, second malignancies and overall survival.

209

210 Our study has several limitations, including heterogeneity in the patient population and time of
211 sampling, and the unavailability of pre-transplant graft material. Additionally, by focusing on very
212 long-term survivors, HCT recipients with severe post-HCT complications may be underrepresented in
213 our study cohort, as these complications may impact their long-term survival and/or ability to enroll.
214 Accordingly, the lack of association between CH and aGvHD needs to be interpreted with caution.
215 Yet, from a clinical perspective, our findings remain relevant, since long-term HCT related effects are
216 only relevant for those who survive. Finally, the association between CH, serotherapy, CRP and post-
217 HCT viral reactivations does not indicate causality. In fact, many of these processes are linked, for
218 example, serotherapy-induced T-cell depletion is associated with increased risk of viral reactivations.
219 In addition, the presence of CH itself may affect the HCT-associated inflammatory processes. Future
220 studies, including longitudinal sampling of both donor and recipient, may help understand how
221 different aspects of HCT (e.g., mobilization, engraftment, forced proliferation, inflammation) affect
222 the prevalence and dynamics of post-transplant CH.

223

224 In summary, pediatric HCT recipients are at increased risk of CH at a young age, emphasizing the
225 importance of prospective screening. Insight into the longitudinal dynamics of CH post-HCT will be
226 crucial to understanding the underlying mechanisms and to determine its potential impact on post-
227 transplant health.

228

229 **Acknowledgements**

230 This study was financially supported by a VENI grant of the Netherlands Organization for Scientific
231 Research (NWO) (grant number VI.Veni.202.021 to MEB), a physician scientist grant of the European
232 Hematology Association (to MEB), a John Hansen research grant from the DKMS and a KiKa project
233 grant (project number 418). The KiKa project grant supported the salary of KFM. The funders had no
234 role in the design, execution or writing of this work, nor in the decision to submit results. We would

235 like to thank M.C.H. de Groot for extracting historical laboratory data from the Utrecht Patient
236 Oriented Database.

237

238 **Authorship Contributions**

239 Conceptualization: All authors. Data analysis and figures: KFM, MvB, AdG, MEB. Writing (original
240 draft): KFM and MEB. Writing (review and editing): All authors. All authors have read and agreed to
241 the published version of the manuscript.

242

243 **Disclosure of conflicts of interest**

244 DSN has stocks in Madrigal Pharmaceuticals. SN was advisor for Sobi. CAL is on a data and safety
245 monitoring board for ExCellThera and was medical advisor for Sobi and Orchard Therapeutics.

246 **Reference list**

- 247 1. Jaiswal, S. *et al.* Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. *N.*
248 *Engl. J. Med.* **371**, 2488–2498 (2014).
- 249 2. Genovese, G. *et al.* Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA
250 Sequence. *N. Engl. J. Med.* **371**, 2477–2487 (2014).
- 251 3. Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. *Science (80-.).* **366**,
252 (2019).
- 253 4. Zink, F. *et al.* Clonal hematopoiesis, with and without candidate driver mutations, is common
254 in the elderly. *Blood* **130**, 742–752 (2017).
- 255 5. van Zeventer, I. A. *et al.* Evolutionary landscape of clonal hematopoiesis in 3,359 individuals
256 from the general population. *Cancer Cell* **41**, 1017-1031.e4 (2023).
- 257 6. Fabre, M. A. *et al.* The longitudinal dynamics and natural history of clonal haematopoiesis.
258 *Nat. 2022 6067913* **606**, 335–342 (2022).
- 259 7. Wong, W. H., Bhatt, S. & Trinkaus, K. Engraftment of rare, pathogenic donor hematopoietic
260 mutations in unrelated hematopoietic stem cell transplantation. *Sci. Transl. Med.* **12**, (2020).
- 261 8. Gibson, C. J. *et al.* Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
262 *J. Clin. Oncol.* **40**, 189 (2022).
- 263 9. Boettcher, S. *et al.* Clonal hematopoiesis in donors and long-term survivors of related
264 allogeneic hematopoietic stem cell transplantation. *Blood* **135**, 1548–1559 (2020).
- 265 10. Campbell, P., Chapman, M. S., Wilk, M. & Boettcher, S. Clonal dynamics after allogeneic
266 haematopoietic cell transplantation using genome-wide somatic mutations.
267 doi:10.21203/rs.3.rs-2868644/v1.
- 268 11. Frick, M. *et al.* Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell
269 transplantation. *J. Clin. Oncol.* **37**, 375–385 (2019).
- 270 12. van Bergen, M. G. J. M. *et al.* Characterization of a genomic region 8 kb downstream of GFI1B
271 associated with myeloproliferative neoplasms. *Biochim. Biophys. Acta - Mol. Basis Dis.* **1867**,

- 272 166259 (2021).
- 273 13. Ten Berg, M. J. *et al.* Linking laboratory and medication data: New opportunities for
274 pharmacoepidemiological research. *Clin. Chem. Lab. Med.* **45**, 13–19 (2007).
- 275 14. Xie, M. *et al.* Age-related cancer mutations associated with clonal hematopoietic expansion.
276 *Nat. Med.* **20**, 1472 (2014).
- 277 15. Abelson, S. *et al.* Prediction of acute myeloid leukaemia risk in healthy individuals. *Nature* **559**,
278 400–404 (2018).
- 279 16. Brodska, H. *et al.* Marked increase of procalcitonin after the administration of anti-thymocyte
280 globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a
281 prospective study. *Crit. Care* **13**, R37–R37 (2009).
- 282 17. Baker, K. S., Bresters, D. & Sande, J. E. The burden of cure: Long-term side effects following
283 Hematopoietic Stem Cell Transplantation (HSCT) in children. *Pediatric Clinics of North America*
284 vol. 57 323–342 at <https://doi.org/10.1016/j.pcl.2009.11.008> (2010).
- 285 18. Florez, M. A. *et al.* Clonal hematopoiesis: Mutation-specific adaptation to environmental
286 change. *Cell Stem Cell* **29**, 882–904 (2022).
- 287 19. Kim, K. H. *et al.* Clonal hematopoiesis in the donor does not adversely affect long-term
288 outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year
289 follow-up. *Haematologica* **108**, 1817–1826 (2023).
- 290 20. Williams, N. *et al.* Life histories of myeloproliferative neoplasms inferred from phylogenies.
291 *Nature* **602**, 162–168 (2022).
- 292 21. Ford, A. M., Colman, S. & Greaves, M. Covert pre-leukaemic clones in healthy co-twins of
293 patients with childhood acute lymphoblastic leukaemia. *Leuk. 2022 371* **37**, 47–52 (2022).
- 294 22. Carreras, E., Dufour, C., Mohty, M. & Kröger, N. The EBMT Handbook: Hematopoietic Stem
295 Cell Transplantation and Cellular Therapies [Internet]. *EBMT Handb. Hematop. Stem Cell*
296 *Transplant. Cell. Ther.* 1–702 (2019) doi:10.1007/978-3-030-02278-5.
- 297 23. Armenian, S. H. & Chow, E. J. Cardiovascular disease in survivors of hematopoietic cell

298 transplantation. *Cancer* **120**, 469 (2014).

299 24. Rhee, J. W. *et al.* Clonal Hematopoiesis and Cardiovascular Disease in Patients with Multiple
300 Myeloma Undergoing Hematopoietic Cell Transplant. *JAMA Cardiol.* **9**, 16–24 (2024).

301 25. Kato, M. *et al.* Donor cell-derived hematological malignancy: A survey by the Japan Society for
302 Hematopoietic Cell Transplantation. *Leukemia* **30**, 1742–1745 (2016).

303

304

305 **Tables**

306 **Table 1**

Determinant	Total (n = 144)	CH (n = 23)	No CH (n = 121)	P value
Recipient sex				
Male	83 (58%)	13 (57%)	70 (58%)	1
Recipient age at Inclusion; (years, median, IQR)	20.5 16.2-27.7	28.3 (19.4-33.2)	20.2 (15.9-25.7)	0.03
Recipient age at HCT; (years, median, IQR)	8.0 4.0-12.3	7.3 (3.6-15.3)	8.0 (4.1-6.7)	0.59
HSC age; (years, median, IQR)	32.1 15.6-43.7	44.0 (34.7-51.4)	29.6 (14.2-42.0)	<0.01
Donor age at HCT; (years, median, IQR)	13.5 5.1-26.8	30.2 (19.6-36.4)	11.6 (4.3-25.1)	<0.01
Follow-up time; (years, median, IQR)	12.1 8.0-17.9	18.4 (8.5-22.8)	11.6 (7.9-16.1)	0.07
Underlying disease				
Hemato-oncology	116 (81%)	21 (91%)	95 (79%)	0.33
Bone marrow failure syndromes	24 (17%)	2 (9%)	22 (18%)	
Immunodeficiency	4 (3%)	0 (0%)	4 (3%)	
Stem cell source				
Bone marrow	101 (70%)	18 (78%)	83 (69%)	0.01
Cord blood	33 (23%)	1 (4%)	32 (26%)	
Peripheral blood	10 (7%)	4 (17%)	6 (5%)	
Relation to donor				
Unrelated	84 (58%)	16 (70%)	68 (56%)	0.21
Family	60 (42%)	7 (30%)	53 (44%)	
Sibling	53 (37%)	5 (22%)	48 (40%)	
Parent	7 (5%)	2 (9%)	5 (4%)	
Conditioning				
Chemotherapy-based	112 (78%)	18 (78%)	99 (78%)	1
TBI-based	32 (22%)	5 (22%)	27 (22%)	
Myeloablative	134 (93%)	20 (87%)	114 (94%)	1
Non-myeloablative	10 (7%)	3 (13%)	7 (6%)	
Serotherapy				
Yes	87 (60%)	20 (87%)	68 (56%)	0.01
No	54 (38%)	3 (13%)	53 (44%)	

307

308

309 **Table Legends**

310 **Table 1. HCT characteristics for study cohort.** P values calculated from Chi-squared test or Fisher-exact test if expected count <5

311 (categorical variables) or Wilcoxon rank-sum test (continuous variables). Serotherapy consisted of either anti-thymocyte globulin or

312 alemtuzumab (Campath). Abbreviations: CH: clonal hematopoiesis; IQR: interquartile range; HCT: Hematopoietic stem cell transplantation;

313 HSC: hematopoietic stem cell; TBI: Total body irradiation.

314 **Figure Legends**

315

316 **Figure 1. CH is common after HCT at pediatric age. A)** Study design. **B)** Oncoprint of all HCT recipients,
317 sorted by identified CH mutation (red) and variant allele frequency (VAF, orange bars). A darker shade
318 indicates multiple mutations in the same gene. Relation to donor (blue) and stem cell source (yellow)
319 are indicated.

320 *Abbreviations: HCT: hematopoietic cell transplantation; NGS: next generation sequencing; CH: clonal*
321 *hematopoiesis; VAF: variant allele frequency; MUD: matched unrelated donor; BM: bone marrow;*
322 *PBSC: peripheral blood stem cells; CB: cord blood.*

323

324 **Figure 2. Comparison of CH in HCT recipients and controls. A)** Cumulative prevalence of CH plotted
325 against HSC age, split by cohort. P values are derived from a multivariable logistic regression model
326 with cohort (HCT recipient versus control) and HSC age as determinants and CH status as outcome. **B)**
327 Bar plot of HSC age in individuals with and without CH for both cohorts. **C-E)** Bar plots of donor age,
328 follow-up time and recipient age in HCT recipients with and without CH. **F)** Forest plot depicting the
329 effect of timespans from C-E on CH prevalence in logistic regression models with CH status as outcome.
330 The multivariate model includes all three timespans. **G)** Violin plot of variant allele frequencies (VAF)
331 of CH clones in controls and HCT recipients. **H)** Scatterplot of VAF of largest CH clone per individual
332 versus HSC age. Linear regression is calculated for each cohort separately, excluding the outliers with
333 VAF >0.30 in the HCT Recipient cohort. P values in B-E and G are calculated using Wilcoxon rank-sum
334 test.

335 *Abbreviations: HCT: hematopoietic cell transplantation; HSC: hematopoietic stem cell; CH: clonal*
336 *hematopoiesis.*

337

338 **Figure 3. Clinical factors associated with prevalence of CH. A)** Forest plot showing the effect of clinical
339 characteristics on CH prevalence of univariable and multivariable logistic regression models. Stem cell

340 source was corrected for donor age, CD34 dose was corrected for stem cell source and serotherapy
341 was corrected for relation to donor. **B)** CRP measurements around HCT in individuals with and without
342 CH. Lines indicate LOESS regression with 95% confidence interval. **C)** Box plots demonstrating the
343 highest CRP measured within 5-day intervals around graft infusion, split by serotherapy (yes/no) and
344 CH status. P values are calculated using Wilcoxon rank-sum test. **D-E)** Prevalence of CH in individuals
345 with and without viral reactivations, including CMV, EBV and adenovirus reactivation (D) and with and
346 without severe acute graft-versus-host disease (E). P values are calculated using Chi-squared test.
347 *Abbreviations: CH: clonal hematopoiesis; CB: cord blood; BM: bone marrow; PBSC: peripheral blood*
348 *stem cells; MUD: matched unrelated donor; TBI: total body irradiation; aGvHD: acute graft-versus*
349 *host-disease; HSC: hematopoietic stem cell; CRP: C-reactive protein; HCT: hematopoietic cell*
350 *transplantation; CMV: cytomegalovirus; EBV: Epstein-Barr virus; ADV: adenovirus.*

Figure 1




Figure 2

All rights reserved. No reuse allowed without permission.




Figure 3

All rights reserved. No reuse allowed without permission.

